Baumgarten C R, Nichols R C, Naclerio R M, Proud D
J Immunol. 1986 Aug 15;137(4):1323-8.
We have previously demonstrated that a mixture of bradykinin and lysylbradykinin is generated in nasal secretions during the immediate allergic response to allergen. The present studies were performed to determine whether glandular kallikrein plays a role in kinin formation during the allergic reaction. Allergic individuals (n = 7) and nonallergic controls (n = 7) were challenged intranasally with appropriate allergen, and nasal lavages obtained before and after challenge were assayed for immunoreactive glandular kallikrein as well as for histamine, kinins, and N-alpha-tosyl-L-arginine methyl esterase (TAME-esterase) activity. The increase in postchallenge immunoreactive glandular kallikrein levels above baseline was significantly greater (p less than 0.01) for the allergic group (16.3 +/- 14 ng/ml; means +/- SD) than for the nonallergic controls (1.0 +/- 1.9 ng/ml). Increased levels of immunoreactive glandular kallikrein correlated with increases in kinins, histamine, and TAME-esterase activity and with the onset of clinical symptoms. Characterization of immunoreactive glandular kallikrein purified from postchallenge lavages by immunoaffinity chromatography confirmed the identity of this material as an authentic glandular kallikrein on the basis of its inhibition by protease inhibitors and by monospecific antibody to tissue kallikrein, its chromatographic behavior on gel filtration, and its ability to generate lysylbradykinin from highly purified human low m.w. kininogen. The specific activity of this purified material, in terms of kinin generation from kininogen, was very similar to that for authentic glandular kallikrein, suggesting that most if not all of the immunoreactive material purified from nasal lavages represented active enzyme. Inhibition studies by using pooled postchallenge lavages suggest that the majority of the kinin generating activity in these samples was due to glandular kallikrein. We conclude, therefore, that glandular kallikrein is secreted during the allergic response and can contribute to the formation of the lysylbradykinin produced during the allergic reaction.
我们之前已经证明,在对过敏原的速发型过敏反应期间,鼻分泌物中会产生缓激肽和赖氨酰缓激肽的混合物。进行本研究以确定腺体激肽释放酶在过敏反应期间的激肽形成过程中是否发挥作用。对过敏个体(n = 7)和非过敏对照(n = 7)进行鼻腔内给予适当的过敏原刺激,对刺激前后获得的鼻腔灌洗液检测免疫反应性腺体激肽释放酶以及组胺、激肽和N-α-甲苯磺酰-L-精氨酸甲酯酶(TAME-酯酶)活性。过敏组(16.3±14 ng/ml;均值±标准差)刺激后免疫反应性腺体激肽释放酶水平高于基线的增加幅度显著大于(p < 0.01)非过敏对照组(1.0±1.9 ng/ml)。免疫反应性腺体激肽释放酶水平的升高与激肽、组胺和TAME-酯酶活性的增加以及临床症状的出现相关。通过免疫亲和层析从刺激后灌洗液中纯化的免疫反应性腺体激肽释放酶的特性,基于其被蛋白酶抑制剂和组织激肽释放酶单特异性抗体抑制、其在凝胶过滤上的色谱行为以及其从高度纯化的人低分子量激肽原产生赖氨酰缓激肽的能力,证实该物质为真正的腺体激肽释放酶。就从激肽原产生激肽而言,这种纯化物质的比活性与真正的腺体激肽释放酶非常相似,表明从鼻腔灌洗液中纯化的免疫反应性物质大部分(如果不是全部)代表活性酶。使用合并的刺激后灌洗液进行的抑制研究表明,这些样品中大部分激肽生成活性归因于腺体激肽释放酶。因此,我们得出结论,腺体激肽释放酶在过敏反应期间分泌,并且可有助于过敏反应期间产生的赖氨酰缓激肽的形成。